Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
EHA Library - The official digital education library of European Hematology Association (EHA)
Progression-free (dashed line) and overall survival (solid line) with... | Download Scientific Diagram
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Multiple Myeloma with a Special Focus on Precision Medicine | Published in healthbook TIMES Oncology Hematology
NEJM on X: "New research into elotuzumab plus pomalidomide and dexamethasone for #MultipleMyeloma explained in Quick Take video: https://t.co/Aa2Q1U86zg https://t.co/YJK9tdF7wE" / X
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma | Cancer Chemotherapy and Pharmacology
Elotuzumab (Empliciti) Drug Info
FDA
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma | MedPage Today
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial
Empliciti (elotuzumab) for the Treatment of Multiple Myeloma, USA
Elotuzumab
Combination Therapies - POMALYST® (pomalidomide)
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
Continuous Elotuzumab, Pomalidomide and Dexamethasone Maintenance Following Second Autologous Transplant for Multiple Myeloma: Results of a Prospective, Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
